newsfilter
← Latest News
GlobeNewswire·

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

ZNTL
  • Zentalis Pharmaceuticals announced that ASCO accepted an abstract for presentation at the 2026 ASCO Annual Meeting held June 1-5 in Chicago.
  • The accepted abstract covers Part 1 of the MUIR trial, focusing on azenosertib combined with paclitaxel for platinum-resistant ovarian cancer (PROC).
  • The presentation is scheduled for June 1, 2026, during the Poster Session on Gynecologic Cancer (Poster Board 195).
  • MUIR (ZN-c3-002) is a Phase 1b trial evaluating azenosertib combinations with carboplatin, gemcitabine, pegylated liposomal doxorubicin, or paclitaxel.
  • Part 2 of the MUIR trial evaluates azenosertib plus bevacizumab as a maintenance regimen for advanced ovarian, peritoneal, or fallopian tube cancer.
  • Azenosertib is a first-in-class oral WEE1 inhibitor targeting Cyclin E1-positive PROC, which represents approximately 50% of PROC patients.
  • The U.S. FDA granted Fast Track Designation to azenosertib for treating Cyclin E1-positive platinum-resistant ovarian cancer.
  • Zentalis is advancing azenosertib in registration-intended monotherapy trials (DENALI & ASPENOVA) while the MUIR trial explores combination strategies.
  • Validation of the Cyclin E1 companion diagnostic assay is ongoing within the DENALI & ASPENOVA trials.